GLP-1 Policy & Pricing News (2026)
Trump administration actions, Medicare coverage, pricing reforms, and the regulatory landscape for GLP-1 medications in 2026.
Trump Administration on GLP-1 Pricing
The 2025 Trump administration has signaled focus on prescription drug costs broadly, with specific attention to GLP-1 medications given their high list prices and growing demand. Specific actions in development:
- Continued IRA Medicare price negotiation (includes some GLP-1s)
- Potential expanded compounding pathways
- Most-favored-nation pricing proposals revived
- Pressure on manufacturer rebate structures
Final policy positions are evolving. Patient impact remains to be seen as of April 2026.
Medicare Coverage Status
- Type 2 diabetes: covered (Ozempic, Mounjaro, Rybelsus, Trulicity, Victoza)
- Weight loss alone: generally NOT covered
- Wegovy CV indication: covered for adults with obesity + established heart disease (2024 expansion)
- Pending legislation: Treat and Reduce Obesity Act (TROA) would expand coverage if passed
Manufacturer Pricing Changes
- LillyDirect Zepbound vials launched 2024 at $349/mo (vs. $1,069 autoinjector)
- NovoCare expanded patient assistance for Wegovy uninsured patients
- Eli Lilly added 7.5 mg and 10 mg Zepbound vials at progressive pricing
Frequently Asked Questions
Will Trump lower GLP-1 prices?
The 2025 administration has signaled interest in lowering prescription drug costs. Specific GLP-1 actions include negotiated Medicare prices for older drugs and potential expanded compounding pathways. No final policy as of April 2026.
Does Medicare cover GLP-1 for weight loss?
Generally not — except for the 2024 Wegovy CV indication, which opened access for some Medicare patients with established heart disease. Legislation to expand coverage has been proposed but not passed.
What is the inflation reduction act doing for GLP-1?
IRA Medicare price negotiation includes some GLP-1s in early rounds (focused on T2D indications). Final negotiated prices begin taking effect in stages from 2026 onward.